Dr. med. Arthur Filusch Dr. med. M. Natour FESC und Partner Ihre Privatklinik für
Innere medizin, Kardiologie und Pneumologie
studium der humanmedizin an der Ruprecht-Karls-
Fellow of the European Society of Cardiology european Cardiologist
Blutdruckspezialist der Deut-schen hochdruck Liga (DhL)
Promotionsarbeit: „Kontrastechokardiographische
Untersuchungen zur Beurteilung der myokardperfusion und kardioprotektiver therapieansätze im experimentellen
Herzkatheter- und Operationsräume
Infarkt-Reperfusionsmodell “, Prof. Dr. h. Kücherer,
Klinik für Innere medizin III, Kardiologie, Angiologie,
Pneumologie, Universität heidelberg, „suma cum laude“. Berufslaufbahn Praxisklinik- und Studienräume
Arzt im Praktikum an der medizinischen Klinik III
Abteilung für Kardiologie, Angiologie und Pneumologie,
Pneumologische Ausbildung, Abteilung für
(hauptschlagader, Nieren-arterien, halsschlagader,
Oberarzt des pneumologischen schwerpunkts und
Leiter der spezialambulanz für pulmonale hypertonie
Abteilung für Kardiologie, Angiologie und Pneumologie, Universitätsklinikum heidelberg.
eintritt in die heidelberger Praxisklinik für Kardiologie Dr. Natour und Partner.
heart meets science Publikationen
soluble tWeAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension. Filusch A, Zelniker t, Baumgärtner C, eschricht s, Frey N, Katus hA, Chorianopoulos e. Clin Res Cardiol. 2011 Oct;100(10):879-85. doi: 10.1007/s00392-011-0318-z. Epub 2011 Apr 11. ____
Respiratory muscle dysfunction in congestive heart failure--the role of pulmonary hypertension. Filusch A, ewert R, Altesellmeier m, Zugck C, hetzer R, Borst mm, Katus hA, meyer FJ. Int J Cardiol. 2011 Jul 15;150(2):182-5. Epub 2010 May 4. ____
high-sensitive troponin t: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. Filusch A, Giannitsis e, Katus hA, meyer FJ. Clin Sci (Lond). 2010 Jun 2;119(5):207-13. ____
strain and strain rate echocardiography for evaluation of right ventricular dysfunction in patients with idiopathic pulmonary arterial hypertension. Filusch A, mereles D, Gruenig e, Buss s, Katus hA, meyer FJ. Clin Res Cardiol. 2010 Aug;99(8):491-8. Epub 2010 Mar 30. ____
endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension. Droste As, Rohde D, Voelkers m, Filusch A, Bruckner t, Borst mm, Katus hA, meyer FJ. Respir Res. 2009 Dec 30;10:129. ____
echocardiographic phase imaging to predict reverse remodeling after cardiac resynchronization therapy. Buss sJ, humpert Pm, Bekeredjian R, hardt se, Zugck C, schellberg D, Bauer A, Filusch A, Kuecherer h, Katus hA, Korosoglou G. JACC Cardiovasc Imaging. 2009 May;2(5):535-43. ____
Fatal varicella in an immunocompromised adult associated with a european genotype e2 variant of varicella zoster virus. springfeld C, sauerbrei A, Filusch A, Konstandin m, hartschuh W, sauer P, encke J, stremmel W, schnitzler P. J Clin Virol. 2009 Jan;44(1):70-3. Epub 2008 Dec 3.
evaluation cardioprotective effects of atorvastatin in rats by real time myocardial contrast echocardiography. Filusch A, Buss s, hardt s, Katus hA, Kuecherer hF, hansen A. Echocardiography. 2008 Oct;25(9):974-81. Epub 2008 Sep 2. ____
skeletal muscle dysfunction in patients with idiopathic pulmonary arterial hypertension. Bauer R, Dehnert C, schoene P, Filusch A, Bärtsch P, Borst mm, Katus hA, meyer FJ. Respir Med. 2007 Nov;101(11):2366-9. Epub 2007 Aug 6. ____
evidence of left ventricular contractile asynchrony by echocardiographic phase imaging in patients with type 2 diabetes mellitus and without clinically evident heart disease. Korosoglou G, humpert Pm, halbgewachs e, Bekeredjian R, Filusch A, Buss sJ, morcos m, Bierhaus A, Katus hA, Nawroth PP, Kuecherer h. Am J Cardiol. 2006 Dec 1;98(11):1525-30. Epub 2006 Oct 16. ____
Immediate and chronic effects of AV-delay optimization in patients with cardiac resynchronization therapy. hardt se, Yazdi sh, Bauer A, Filusch A, Korosoglou G, hansen A, Bekeredjian R, ehlermann P, Remppis A, Katus hA, Kuecherer hF. Int J Cardiol. 2007 Feb 14;115(3):318-25. Epub 2006 Aug 7. ____
Cardioprotective effects of the novel selective endothelin-A receptor antagonist BsF 461314 in ischemia-reperfusion injury. hansen A, Bekeredjian R, Filusch A, Wolf D, Gross mL, mueller s, Korosoglou G, Kuecherer hF. J Am Soc Echocardiogr. 2005 Nov;18(11):1213-20. ____
Usefulness of myocardial parametric imaging to evaluate myocardial viability in experimental and in clinical studies. Korosoglou G, hansen A, Bekeredjian R, Filusch A, hardt s, Wolf D, schellberg D, Katus hA, Kuecherer h. Heart. 2006 Mar;92(3):350-6. Epub 2005 Jun 6. ____
Fourier phase analysis can be used to objectively analyze real-time myocardial contrast echocardiograms. hansen A, Bekeredjian R, Korosoglou G, Wolf D, Filusch A, Kuecherer hF. Int J Cardiovasc Imaging. 2004 Aug;20(4):241-8. ____
evaluation of cardioprotective effects of recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in myocardial ischemia-reperfusion injury by real-time myocardial contrast echocardiography. hansen A, Kumar A, Wolf D, Frankenbergerova K, Filusch A, Gross mL, mueller s, Katus h, Kuecherer h. J Am Coll Cardiol. 2004 Aug 18;44(4):887-91. ____
Fourier phase and amplitude analysis for automated objective evaluation of myocardial contrast echocardiograms. Bekeredjian R, hilbel t, Filusch A, hansen A, Benz A, Zehelein J, Kuecherer hF. Int J Cardiovasc Imaging. 2003 Apr;19(2):117-28. ____
Detection of acute myocardial ischemia during pharmacological stress in graded coronary artery stenosis: analysis of left ventricular asynchrony using Fourier phase imaging in pigs. hansen A, hardt se, Pekrul I, Filusch A, Bekeredjian R, Kuecherer hF. Int J Cardiovasc Imaging. 2003 Apr;19(2):107-15. ____
Cyclic variation of myocardial signal intensity in real-time myocardial perfusion imaging. Bekeredjian R, hansen A, Filusch A, Dubart Ae, Da silva KG Jr, hardt ss, Korosoglou G, Kuecherer hF. J Am Soc Echocardiogr. 2002 Dec;15(12):1425-31.
BURKINA –FASO DÉCRET N° 96- 355/ PRES/PM/METSS ********** Portant liste des maladies professionnelles LA PATRIE OU LA MORT, NOUS VAINCRONS ! ************** LE PRÉSIDENT DU FASO PRÉSIDENT DU CONSEIL DES MINISTRES *************************** Le Décret n°96-039/PRES du 06 Février 1996 portant nomination Le Décret n° 96 335/PRES/PM du 03 septembre 1996
Curriculum Vitae (Hung-Rong Yen) Name: Hung-Rong Yen (顏宏融) Birth date: October 19, 1972. Birth Place: Changhua County, Taiwan Citizenship: Taiwan, R.O.C. Office Address: Center for Traditional Chinese Medicine, E-mail: coloryen@adm.cgmh.org.tw Language: Taiwanese, Chinese, English Education and Post-Graduate Education: Sep 1990-Jun 1997 M.D., China Medica